Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
Bruton’s Tyrosine Kinase (BTK) is considered crucial in the activation and survival of both physiological and malignant B-cells. In recent years, ibrutinib, an oral BTK inhibitor, became a breakthrough therapy for hematological malignancies, such as chronic lymphocytic. However, ibrutinib’s feasibil...
Enregistré dans:
| Auteurs principaux: | , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI AG
2022-04-01
|
| Collection: | Cells |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/2073-4409/11/8/1338 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|